From: Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Toxicity
Grade 1
Grade 2
Grade 3
Grade 4
n(%)
Bleeding
2 (5.7)
-
Protenuria
3 (8.5)
4 (11.4)
Hypertension
1 (2.8)
Neurotoxicity
LVS disfunction
Other events
Pneumonia 1 (2.8)